Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
77
KRYS Quote, Financials, Valuation and Earnings
Last price:
$251.44
Seasonality move
:
5.72%
Day range:
$248.90 - $255.00
52-week range:
$122.80 - $255.00
Dividend yield:
0%
P/E ratio:
38.00x
P/S ratio:
20.26x
P/B ratio:
6.46x
Volume:
220.5K
Avg. volume:
298.7K
1-year change:
57.53%
Market cap:
$7.3B
Revenue:
$290.5M
EPS (TTM):
$6.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
$93.4M | $1.12 | 16.27% | 5.57% | $229.00 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -44.74% | $9.67 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
DXCM
DexCom, Inc.
|
$1.2B | $0.57 | 11.43% | 70.31% | $85.27 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
$253.36 | $229.00 | $7.3B | 38.00x | $0.00 | 0% | 20.26x |
|
ADMA
ADMA Biologics, Inc.
|
$19.50 | $25.67 | $4.6B | 22.89x | $0.00 | 0% | 9.81x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.05 | $9.67 | $303.5M | -- | $0.00 | 0% | -- |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$398.51 | $491.92 | $52.6B | 1,657.01x | $0.00 | 0% | 16.35x |
|
DXCM
DexCom, Inc.
|
$66.86 | $85.27 | $26.1B | 37.21x | $0.00 | 0% | 6.03x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.84 | $11.75 | $404.2M | -- | $0.00 | 0% | 1.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
0.83% | 0.141 | 0.19% | 9.43x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
DXCM
DexCom, Inc.
|
48.58% | 1.694 | 9.81% | 1.33x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Krystal Biotech, Inc. vs. Competitors
-
Which has Higher Returns KRYS or ADMA?
ADMA Biologics, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 27.14%. Krystal Biotech, Inc.'s return on equity of 19.91% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About KRYS or ADMA?
Krystal Biotech, Inc. has a consensus price target of $229.00, signalling downside risk potential of -9.62%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 29.11%. Given that ADMA Biologics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.10 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is KRYS or ADMA More Risky?
Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock KRYS or ADMA?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or ADMA?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Krystal Biotech, Inc.'s net income of $79.4M is higher than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.00x while ADMA Biologics, Inc.'s PE ratio is 22.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.26x versus 9.81x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M ADMAADMA Biologics, Inc.9.81x 22.89x $134.2M $36.4M
-
Which has Higher Returns KRYS or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of --. Krystal Biotech, Inc.'s return on equity of 19.91% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About KRYS or ALDX?
Krystal Biotech, Inc. has a consensus price target of $229.00, signalling downside risk potential of -9.62%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 74.49%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.10 1 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is KRYS or ALDX More Risky?
Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock KRYS or ALDX?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or ALDX?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Krystal Biotech, Inc.'s net income of $79.4M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.00x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.26x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns KRYS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 20.1%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About KRYS or ALNY?
Krystal Biotech, Inc. has a consensus price target of $229.00, signalling downside risk potential of -9.62%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 20.65%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.10 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is KRYS or ALNY More Risky?
Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock KRYS or ALNY?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or ALNY?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Krystal Biotech, Inc.'s net income of $79.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.00x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,657.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.26x versus 16.35x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M
-
Which has Higher Returns KRYS or DXCM?
DexCom, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 23.47%. Krystal Biotech, Inc.'s return on equity of 19.91% beat DexCom, Inc.'s return on equity of 30.94%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B DXCMDexCom, Inc.61.8% $0.70 $5.3B -
What do Analysts Say About KRYS or DXCM?
Krystal Biotech, Inc. has a consensus price target of $229.00, signalling downside risk potential of -9.62%. On the other hand DexCom, Inc. has an analysts' consensus of $85.27 which suggests that it could grow by 27.53%. Given that DexCom, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe DexCom, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.10 1 0 DXCMDexCom, Inc.20 4 0 -
Is KRYS or DXCM More Risky?
Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.513, suggesting its more volatile than the S&P 500 by 51.265%.
-
Which is a Better Dividend Stock KRYS or DXCM?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or DXCM?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. Krystal Biotech, Inc.'s net income of $79.4M is lower than DexCom, Inc.'s net income of $283.8M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.00x while DexCom, Inc.'s PE ratio is 37.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.26x versus 6.03x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M DXCMDexCom, Inc.6.03x 37.21x $1.2B $283.8M
-
Which has Higher Returns KRYS or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of -40.15%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About KRYS or VNDA?
Krystal Biotech, Inc. has a consensus price target of $229.00, signalling downside risk potential of -9.62%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 71.78%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.10 1 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is KRYS or VNDA More Risky?
Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock KRYS or VNDA?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or VNDA?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Krystal Biotech, Inc.'s net income of $79.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.00x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.26x versus 1.89x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
